

December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2011-000631-92/ Novartis Protocol ID CQGE031A2208

*A phase II, randomized, double-blind, placebo controlled, parallel design, dose ranging, multi-center trial of four levels of exposure of QGE031 s.c. for 16 weeks in subjects aged 18 years and older with peanut allergy*

Trial CQGE031A2208 was cancelled with no patient enrollment and as such, no results will be reported.